Theraclion : Présentation AGM – 29 juin 2023

AGM

Présentation

Yann Duchesne

Martin Deterre

David Auregan

Paris - 29 juin 2023

Déroulé de l'Assemblée Générale Mixte

Malakoff, le 29 juin 2023

• Ouverture de l'assemblée par le Président
• Constitution du bureau
• • Président Yann Duchesne
  • Scrutateurs Claude Lenoir et François Lacoste
  • Secrétaire Laurent Beauvoit
• Annonce du quorum AGO&AGE 27 344 742 voix soit 58,84% / Dépôts des documents sur le bureau
• Présentation de l'activité au cours de l'exercice clos le 31 décembre 2022
• Présentation des comptes de l'exercice clos le 31 décembre 2022
• Présentation des rapports du commissaire aux comptes
• Présentation par le Secrétaire des résolutions
• Clôture de l'assemblée

2 © 2022 Theraclion

Management

Présentation de l'activité 2023

Martin Deterre

Paris - Juin 2023

OUR AMBITION

OUR MISSION	SHORT TERM
NEXT MILESTONES

To DISRUPT the

VARICOSE VEINS market

and to develop

INNOVATIVE NON-

INVASIVE treatments

By 2026 :

US + China market clearance and fast-track market access

Achieve a MUST-HAVE full

AI+ROBOTIC product:

the new STANDARD OF CARE

for the physician and the patient's BEST OPTION

FDA pivotal trial FIRST

PATIENT in 2023

Start SONOVEIN CHINESE REGISTRATION process end of 2023

First AI feature early 2024

4 © Theraclion - Confidential

LAST 12 MONTHS ACHIEVEMENTS

• SONOVEIN® HD launch in May '22
• Better imaging
• Faster treatments
• 5+ SW releases
• Efficient and reliable

TECHNICAL

• Efficient treatments
• FDA safety study with 95% reflux free
• FDA approved pivotal study IDE
• Near 2000 treatments and counting

CLINICAL

• 10+ KOL with
  SONOVEIN
• Commercial relationship build-up with KOL
• 20+ KOL presentations in top congresses
• First class Chinese strategic partner

COMMERCIAL & PARTNERSHIPS

5 © Theraclion - Confidential

THE TECHNOLOGY

6 © Theraclion - Confidential

THE PRINCIPLE: THERMAL ABLATION

BY HIGH INTENSITY FOCUSED ULTRASOUND (HIFU)

A TREATMENT FROM OUTSIDE THE BODY: NO INCISIONS

Spherical transducer

Concentrates ultrasound wave to the focal point

Focused acoustic wave

Acoustic waves produce thermal

effect only at the focal point,

sparing healthy tissue

Localized tissue
heating at the
focal point	Robotic driven	Real-time ultrasound
	displacements	visualization and control

7 © Theraclion - Confidential

DISRUPTING VARICOSE VEINS TREATMENTS

SONOVEIN

LASER /

RADIOFREQUENCY

SURGERY

From:

INVASIVE

	To:
	MINIMALLY
	INVASIVE
	Sterile environment
	required
Invasive and costly	Current standard
Outdated concept	Needs operating room
Invasive procedure
replaced by endovenous	Staff intensive
in the Western world

From:

MINIMALLY INVASIVE

To:

NON-

INVASIVE

Non-invasive

No sterile

environment required

Immediate return to daily activities

© Theraclion - Confidential

THE VARICOSE VEIN MARKET

AND OUR GO-TO-MARKET STRATEGY

9 © Theraclion - Confidential

VARICOSE VEINS MARKET

$2.1B

Addressable device 1,2

4,300,000

Addressable annual procedures worldwide3

30%

Will be SONOVEIN procedures1,2

PRIMARY VARICOSE

VEINS DEVICE

MARKET

Varicose

veins

market

$2(incl.1Bnon-device-based costs)

SONOVEIN +

other device$1.1B market

$2.1B(3)

Historic

device

market

1. https://www.grandviewresearch.com/industry-analysis/varicose-veins-treatment-devices-market10year projections
   10 (2) https://www.futuremarketinsights.com/reports/varicose -veins-treatment-devices-market

1. Company estimations based on above reports